Integral Health Asset Management LLC Takes $10.82 Million Position in Upstream Bio, Inc. $UPB

Integral Health Asset Management LLC purchased a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 575,000 shares of the company’s stock, valued at approximately $10,816,000.

Several other large investors also recently added to or reduced their stakes in UPB. BNP Paribas Financial Markets raised its stake in Upstream Bio by 229.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after acquiring an additional 2,158 shares during the period. Legal & General Group Plc boosted its position in Upstream Bio by 83.0% during the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after purchasing an additional 1,440 shares during the period. Ameritas Investment Partners Inc. increased its stake in shares of Upstream Bio by 95.3% in the second quarter. Ameritas Investment Partners Inc. now owns 3,558 shares of the company’s stock worth $39,000 after purchasing an additional 1,736 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of Upstream Bio by 1,963.9% in the third quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock worth $57,000 after purchasing an additional 2,887 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its position in shares of Upstream Bio by 133.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 7,833 shares of the company’s stock valued at $86,000 after purchasing an additional 4,483 shares during the period.

Analysts Set New Price Targets

A number of analysts recently commented on UPB shares. Evercore started coverage on shares of Upstream Bio in a research note on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price target on the stock. Lifesci Capital initiated coverage on Upstream Bio in a research note on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a report on Wednesday, January 21st. Finally, Mizuho raised shares of Upstream Bio to a “strong-buy” rating in a research note on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $45.25.

Upstream Bio Stock Performance

Upstream Bio stock opened at $9.23 on Friday. Upstream Bio, Inc. has a fifty-two week low of $5.14 and a fifty-two week high of $33.68. The stock has a market cap of $498.79 million, a P/E ratio of -4.91 and a beta of 2.96. The firm’s fifty day moving average price is $20.05 and its 200-day moving average price is $22.00.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.